AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30092844 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 180
Study 27038050 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Long Term with Active Suicide Program (CLASP) - includes three individual in-person meetings, one significant other/family meeting, and 11 brief phone contacts (15-30 minutes each).
Number of subjects: 0
Study 23722352 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of 1% oestrone cream applied once daily for 24 weeks
Number of subjects: 40
Study 23722352 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream applied once daily for 24 weeks
Number of subjects: 40
Study 22704121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic plexus block (2.5 ml lidocaine 1% plus naropine 0.75%) plus intrarectal local anesthesia (lidocaine 1.5%-nifedipine 0.3% cream)
Number of subjects: 180
Study 22704121 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic nerve block (2.5 ml of the same mixture) plus intrarectal local anesthesia (lidocaine 1.5%-nifedipine 0.3% cream)
Number of subjects: 180
Study 20212376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty (CBA)
Number of subjects: 19
Study 17296646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (n = 109)
Number of subjects: 209
Study 17296646 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 100)
Number of subjects: 209
Study 16145184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea self-management program with 24 supervised exercise sessions
Number of subjects: 100
Study 16145184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea self-management program with 4 supervised exercise sessions
Number of subjects: 100
Study 16145184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea self-management program with no supervised exercise sessions
Number of subjects: 100
Study 11442188 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol solution twice daily
Number of subjects: 25
Study 11442188 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol gel once daily
Number of subjects: 25
Study 11442188 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 25
Study 9776370 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications and counseling (index group)
Number of subjects: 81
Study 9776370 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 81
Study 8152764 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide
Number of subjects: 17
Study 8152764 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (extended treatment)
Number of subjects: 17
Study 8152764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3395668 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release pseudoephedrine suspension (CR)
Number of subjects: 16
Study 3395668 — intervention group
Group type: COMPARATOR
Intervention: Immediate release reference syrup (IR-Sudafed)
Number of subjects: 16
Study 31444706 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 60
Study 31444706 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 60
Study 31444706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28668671 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 36 mg/day
Number of subjects: 298
Study 28668671 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 24 mg/day
Number of subjects: 298
Study 28668671 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine 12 mg/day
Number of subjects: 298
Study 28668671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 25997442 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine-Rotigotine
Number of subjects: 346
Study 25997442 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Rotigotine
Number of subjects: 346
Study 24721615 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier non-pneumatic anti-shock garment intervention
Number of subjects: 0
Study 20851483 — intervention group
Group type: COMPARATOR
Intervention: Conventional advice (control group)
Number of subjects: 1957
Study 19552702 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour sleep group
Number of subjects: 0
Study 19552702 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hour sleep group
Number of subjects: 0
Study 19552702 — intervention group
Group type: COMPARATOR
Intervention: 8-hour sleep group
Number of subjects: 0
Study 17684202 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional beef burger meal with French fries, ketchup, and carbonated lemon-flavored soda (meal 1)
Number of subjects: 24
Study 17684202 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian burger with French fries, ketchup, and carbonated lemon-flavored soda (meal 2)
Number of subjects: 24
Study 17684202 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian burger with salad, fruit, yogurt, and orange juice (meal 3)
Number of subjects: 24
Study 15446505 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetocardiography (MCG) measurements in patients with ischemia
Number of subjects: 62
Study 15446505 — intervention group
Group type: COMPARATOR
Intervention: Magnetocardiography (MCG) measurements in healthy controls
Number of subjects: 62
Study 11154542 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive videodisc with a booklet
Number of subjects: 100
Study 11154542 — intervention group
Group type: COMPARATOR
Intervention: Booklet alone
Number of subjects: 100
Study 9382207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (lmw-heparin) at 1.5-5 IE/kg body weight per hour
Number of subjects: 30
Study 9382207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (lmw-heparin) at 8-15 IE/kg body weight per hour
Number of subjects: 30
Study 9382207 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 8103145 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion (50 micrograms intravenous bolus plus 50 micrograms per h intravenous infusion for 48 h)
Number of subjects: 100
Study 8103145 — intervention group
Group type: COMPARATOR
Intervention: Emergency sclerotherapy with 3% sodium tetradecyl sulphate
Number of subjects: 100
Study 3093305 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms, q.i.d. orally (n = 77)
Number of subjects: 229
Study 3093305 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 300 micrograms, q.i.d. orally (n = 76)
Number of subjects: 229
Study 3093305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 76)
Number of subjects: 229
Study 31919940 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) applied for 8 weeks
Number of subjects: 70
Study 31919940 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 70
Study 31919940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 29504325 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary stenting
Number of subjects: 47
Study 29504325 — intervention group
Group type: COMPARATOR
Intervention: Surgical bypass
Number of subjects: 47
Study 27030533 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish-oil capsules (800 mg DHA/d)
Number of subjects: 1531
Study 27030533 — intervention group
Group type: COMPARATOR
Intervention: Vegetable-oil capsules (control group)
Number of subjects: 1531
Study 25519880 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive chemotherapy with praziquantel (exact dosage and duration not specified)
Number of subjects: 12110
Study 25519880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost and coverage data for different intervention arms
Number of subjects: 12110
Study 25519880 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental, political, and other characteristics impacting infection prevalence and intensity
Number of subjects: 12110
Study 23289187 — intervention group
Group type: EXPERIMENTAL
Intervention: Epolyrec (n = 25)
Number of subjects: 50
Study 23289187 — intervention group
Group type: COMPARATOR
Intervention: Eprex (n = 25)
Number of subjects: 50
Study 23289187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Epolyrec and Eprex
Number of subjects: 50
Study 19926918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day)
Number of subjects: 30
Study 19926918 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 30
Study 18230353 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg x 3/day, group A)
Number of subjects: 37
Study 18230353 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (2 mg/day, group G)
Number of subjects: 37
Study 18230353 — intervention group
Group type: COMPARATOR
Intervention: Diet only (group D)
Number of subjects: 37
Study 15722313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 20-25 mg of triamcinolone acetonide
Number of subjects: 136
Study 15722313 — intervention group
Group type: COMPARATOR
Intervention: Focal or panretinal laser treatment
Number of subjects: 136
Study 14511391 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT), phenobarbital, or carbamazepine (CBZ)
Number of subjects: 890
Study 14511391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 890
Study 14511391 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 890
Study 14511391 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) or Carbamazepine (CBZ)
Number of subjects: 890
Study 10498402 — intervention group
Group type: EXPERIMENTAL
Intervention: gly/gly genotype
Number of subjects: 832
Study 10498402 — intervention group
Group type: COMPARATOR
Intervention: asp/asp genotype
Number of subjects: 832
Study 8894058 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD patients during stress condition
Number of subjects: 40
Study 8894058 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD patients during nonstress periods
Number of subjects: 40
Study 8894058 — intervention group
Group type: COMPARATOR
Intervention: Control subjects during nonstress periods
Number of subjects: 40
Study 8319361 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 50
Study 8319361 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 50
Study 8319361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 50
Study 8319361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3522466 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole alone
Number of subjects: 400
Study 3522466 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and cefazolin
Number of subjects: 400
Study 3522466 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and tobramycin
Number of subjects: 400
Study 3522466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 29512336 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary anchorage devices (TADs) used in orthodontic treatment, including 50 (3M ESPE), 56 (Bone screw), and 74 (Morelli) TADs, with lengths of 6, 8, and 10 mm and diameters of 1.5, 1.6, and 1.8 mm, and force levels set at 50, 100, 150, 200, and 250 g.
Number of subjects: 82
Study 27734422 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 0
Study 27734422 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (SWL)
Number of subjects: 0
Study 23949578 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol administration (mean 12.3 mg prior to baseline)
Number of subjects: 175
Study 23949578 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol administration
Number of subjects: 175
Study 23949578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperlactatemia
Number of subjects: 175
Study 21104488 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis with VR imagery
Number of subjects: 35
Study 21104488 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard self-hypnosis
Number of subjects: 35
Study 21104488 — intervention group
Group type: COMPARATOR
Intervention: Relaxation interventions
Number of subjects: 35
Study 19395177 — intervention group
Group type: EXPERIMENTAL
Intervention: SOCRATES questionnaire
Number of subjects: 337
Study 17445348 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicory inulin (CH)
Number of subjects: 45
Study 17445348 — intervention group
Group type: EXPERIMENTAL
Intervention: Jerusalem artichoke inulin (JA)
Number of subjects: 45
Study 17445348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (snack bars without fructans)
Number of subjects: 45
Study 15076203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg without active pretreatment (placebo)
Number of subjects: 10
Study 15076203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg after 5 days' treatment with amiloride 5 mg twice daily
Number of subjects: 10
Study 15076203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg after 5 days' treatment with chlorthalidone 50 mg once daily
Number of subjects: 10
Study 15076203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no active drugs)
Number of subjects: 10
Study 12536532 — intervention group
Group type: EXPERIMENTAL
Intervention: BZX treatment
Number of subjects: 42
Study 12536532 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (control)
Number of subjects: 42
Study 12536532 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (HCG)
Number of subjects: 42
Study 9286940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fradafiban (1 to 15 mg continuously infused over 30 minutes)
Number of subjects: 130
Study 9286940 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefradafiban (single oral doses of 50 mg, 100 mg, and 150 mg)
Number of subjects: 130
Study 9286940 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefradafiban (oral TID for 7 days)
Number of subjects: 130
Study 7964712 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 25
Study 7964712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 25
Study 7964712 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 25
Study 7964712 — intervention group
Group type: COMPARATOR
Intervention: No drug period
Number of subjects: 25
Study 3598611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg orally four times daily
Number of subjects: 40
Study 3598611 — intervention group
Group type: COMPARATOR
Intervention: Combination of N-phosphonacetyl-L-aspartate (PALA) plus L-alanosine
Number of subjects: 40
Study 29359632 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP-V
Number of subjects: 77
Study 29359632 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 77
Study 28682929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (1 mg)
Number of subjects: 0
Study 28682929 — intervention group
Group type: EXPERIMENTAL
Intervention: Safinamide (50 mg or 100 mg)
Number of subjects: 0
Study 28682929 — intervention group
Group type: COMPARATOR
Intervention: Control group (without monoamine oxidase B inhibitor intake)
Number of subjects: 0
Study 28682929 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous oral levodopa intakes
Number of subjects: 0
Study 24967744 — intervention group
Group type: EXPERIMENTAL
Intervention: n-butyl cyanoacrylate (Glubran 2)
Number of subjects: 30
Study 24967744 — intervention group
Group type: COMPARATOR
Intervention: Pelvic lymphadenectomy without n-butyl cyanoacrylate (control)
Number of subjects: 30
Study 24309336 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at a dose of 2 to 2.5 mg/kg as induction dose and sedation maintained with 5 to 10 mg/min.
Number of subjects: 25
Study 24309336 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 25
Study 20451972 — intervention group
Group type: EXPERIMENTAL
Intervention: No scalpel vasectomy with distal vasal flushing (30 mL of sterile water)
Number of subjects: 727
Study 20451972 — intervention group
Group type: COMPARATOR
Intervention: No scalpel vasectomy alone
Number of subjects: 727
Study 19030713 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg, orally in a single dose, 1 hour before bedtime for 21 consecutive days
Number of subjects: 30
Study 19030713 — intervention group
Group type: COMPARATOR
Intervention: Placebo, orally in a single dose, 1 hour before bedtime for 21 consecutive days
Number of subjects: 30
Study 16847677 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-trial (motion sickness induced)
Number of subjects: 11
Study 16847677 — intervention group
Group type: COMPARATOR
Intervention: CN (control trial)
Number of subjects: 11
Study 12514272 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation
Number of subjects: 19
Study 12514272 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine supplementation
Number of subjects: 19
Study 12514272 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline plus Carnitine supplementation
Number of subjects: 19
Study 12514272 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise regimen
Number of subjects: 19
Study 12514272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10664112 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 60
Study 10664112 — intervention group
Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 60
Study 8657519 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg rhSOD
Number of subjects: 26
Study 8657519 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg rhSOD
Number of subjects: 26
Study 8657519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 1724525 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin and guar gum (L + GG 20 g/day)
Number of subjects: 62
Study 1724525 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin and cholestyramine (L + C 16 g/day)
Number of subjects: 62
Study 1724525 — intervention group
Group type: COMPARATOR
Intervention: Comparison of L + C vs L + GG
Number of subjects: 62
Study 6846123 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week rehabilitation program after MI
Number of subjects: 0
Study 6846123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rehabilitation)
Number of subjects: 0
Study 28437553 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental hybrids of C. baccatum var. pendulum
Number of subjects: 9
Study 27187774 — intervention group
Group type: EXPERIMENTAL
Intervention: Single segment/low segments VTS
Number of subjects: 1200
Study 27187774 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 VTS
Number of subjects: 1200
Study 27187774 — intervention group
Group type: COMPARATOR
Intervention: T2/T3 VTS
Number of subjects: 1200
Study 25146918 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-gripping lightweight polyester mesh
Number of subjects: 557
Study 25146918 — intervention group
Group type: COMPARATOR
Intervention: Sutured lightweight polypropylene mesh
Number of subjects: 557
Study 22211678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose chewing gum
Number of subjects: 0
Study 22211678 — intervention group
Group type: COMPARATOR
Intervention: Xylitol chewing gum
Number of subjects: 0
Study 22211678 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20616707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine (50 mg/d)
Number of subjects: 58
Study 20616707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 17703632 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (Apidra®)
Number of subjects: 0
Study 16393213 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication treatment (group 1)
Number of subjects: 145
Study 16393213 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 145
Study 16393213 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-negative group (group 3)
Number of subjects: 145
Study 12359037 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual motivational interview (n=79)
Number of subjects: 160
Study 12359037 — intervention group
Group type: COMPARATOR
Intervention: Self-help booklet (control condition; n=81)
Number of subjects: 160
Study 10459447 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of urinary follicle‐stimulating hormone (FSH, Fostimon 75, A.M.S.A., Italy)
Number of subjects: 60
Study 10459447 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration of urinary follicle‐stimulating hormone (FSH, Metrodin 75 HP, Serono, Italy)
Number of subjects: 60
Study 7818317 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (group D; n = 7)
Number of subjects: 14
Study 7818317 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C; n = 7)
Number of subjects: 14
Study 2354093 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal morphine
Number of subjects: 10
Study 2354093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 90216 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 17
Study 90216 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide
Number of subjects: 17
Study 31622150 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hurricane patients
Number of subjects: 597
Study 31622150 — intervention group
Group type: COMPARATOR
Intervention: Pre-hurricane patients
Number of subjects: 597
Study 28758717 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA+DHA therapy
Number of subjects: 35
Study 28758717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 25827800 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10mg for 4 weeks
Number of subjects: 83
Study 23288871 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 124
Study 23288871 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 124